NCT05039866 - Long-Term Follow-up of Subjects Who Were Treated With ST-920 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 16, 2021

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2039

Conditions

Fabry DiseaseFabry Disease, Cardiac Variant

Interventions

BIOLOGICAL

ST-920

No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.

Trial Locations (13)

3050

The Royal Melbourne Hospital, Parkville

10029

Mt. Sinai Hospital, New York

22030

Lysosomal & Rare Disorders Research & Treatment Center (LDRTC), Fairfax

30322

Emory University School of Medicine, Atlanta

33620

University of South Florida, Tampa

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

52242

University of Iowa Hospital and Clinics, Iowa City

55455

University of Minnesota Medical Center, Minneapolis

92697

University of California, Irvine, Irvine

T2E 7Z4

M.A.G.I.C. Clinic Ltd., Calgary

Unknown

University Hospital of Würzburg, Würzburg

Royal Free Hospital, London

CB2 0QQ

Addenbrooke's Hospital, Cambridge